Endocrine Disorders: Evaluation and Management

  • Author: Todd T. Brown, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 11/14/16 (What's New)


  • Sulfonylureas are considered second line for initial diabetes therapy in the general population
  • Major adverse effects are weight gain and hypoglycemia
  • Liver disease is considered a relative contraindication for sulfonylureas (Management Guidelines)[Diabetes Guidelines]

Action required